Entities / Company
Regeneron Pharmaceuticals.
American pharmaceutical company
- Reports this week
- 2
- Active events
- 3
- Connections
- 266
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
Anne Wojcicki uses her nonprofit to acquire 23andMe amidst a lawsuit led by Letitia James regarding genetic data privacy, while TTAM submitted a higher unsolicited offer than Regeneron.Speculative1 report1 development inside
-
Regeneron Pharmaceuticals and Wave Life Sciences are being compared as healthcare companies.Some support1 report
One to three months ago
-
Sanofi and Regeneron Pharmaceuticals announce a joint initiative to develop Praluent cholesterol medication and initiatives like TrumpRx.gov.Some support1 report1 development inside
-
Sanofi completed the repayment of a development balance.Some support1 report
-
Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.Some support1 report
-
Regeneron Pharmaceuticals filed required reports with the SEC regarding institutional holdings on September 8, 2026.Some support1 report
-
Michael Burry bets on Regeneron recovery despite market skepticism, holds large call positions in UnitedHealth Group, and views Lululemon as undervalued.Some support2 reports
-
MarketBeat provided stock performance data and analyst recommendations for Regeneron Pharmaceuticals and IDEAYA Biosciences.Some support2 reports
-
The National Pension Service increased its stock holdings in Regeneron Pharmaceuticals.Some support1 report
-
FDA approved Pasatru for FOP treatment.Some support2 reports
-
Regeneron Pharmaceuticals has committed to adopting Veeva Vault CRM globally for its commercial teams, utilizing Veeva's specialized platform services.Some support1 report
-
Society for Science and Regeneron Pharmaceuticals jointly announced the results of a prestigious science competition at the National Building Museum.Some support1 report
-
Dodge & Cox grew its stake in Regeneron Pharmaceuticals stock.Some support1 report
-
Regeneron Pharmaceuticals and Biohaven Ltd. announced a clinical supply agreement for combination therapy on August 14, 2026.Some support1 report
-
Market analysis compares the financial performance and outlook of Northwest Biotherapeutics and Regeneron Pharmaceuticals.Some support2 reports
-
Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.Well supported5 reports2 developments inside
-
Regeneron and Sanofi are seeking FDA approval for EYLEA HD pre-filled syringe and discussing collaboration expansion.Some support1 report
-
Regeneron Pharmaceuticals is developing a new facility in the city of Saratoga Springs.Some support1 report
-
Tariffs benefit undervalued AI stocks, and a partnership expands global production footprint for a company.Well supported66 reports50 developments inside
Gone quiet
No new reports in 90+ days-
Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.Some support1 report1 development inside
-
Regeneron conducted the clinical trial for a study related to co-developing new therapies.Some support1 report
-
Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.Some support4 reports
-
Omeros partnered with Novo Nordisk on zaltenibart development, while Intellia and Regeneron formed a collaboration on co-developing therapies. Separately, the FDA approved Omeros' Yartemlea for TA-TMA treatment.Some support1 report
-
Analyst coverage was mentioned in an article regarding Regeneron Pharmaceuticals and Royal Bank of Canada on June 16, 2026.Some support1 report
-
Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.Some support1 report
-
Regeneron Pharmaceuticals operates in Westchester and Hudson Valley, contributing to the local economy and being integrated into the NewYork-Presbyterian system.Some support1 report
-
Regeneron Pharmaceuticals purchased shares in a concurrent private placement, with Leerink Partners serving as part of the underwriting syndicate.Some support1 report
-
Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.Some support6 reports
-
Regeneron Pharmaceuticals received accelerated FDA approval for a drug and partnered with Onco360.Some support1 report
-
Regeneron recorded net product sales of Eylea in the US, and Bayer confirmed its collaboration on the drug's development.Some support1 report
-
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Well supported4 reports12 developments inside
-
Roche and Regeneron Pharmaceuticals are capitalizing on the growing demand for vision care driven by aging populations.Some support1 report
-
Regeneron Pharmaceuticals matched donations to support the Good Days fund.Speculative2 reports
-
Incyte and Regeneron Pharmaceuticals are identified as major players in the immuno-oncology industry.Some support2 reports
-
FDA granted accelerated approval for Regeneron's drug, which is expected for MM cases in the US in 2025.Speculative1 report
-
FDA granted accelerated approval for Lynozyfic, and J.P. Morgan reiterated a Buy rating for the company.Some support4 reports
-
The healthcare sector experienced a discount against the broader market on August 22, 2025, influenced by political uncertainties and government policies targeting prescription drug prices.Some support2 reports2 developments inside
-
RBC raised the price target on Regeneron Pharmaceuticals on July 7, 2025.Speculative1 report
-
MAIA Biotechnology began clinical trials, dosing the first patient in Taiwan and screening in Europe and Asia, with Regeneron providing Libtayo.Some support2 reports
-
Regeneron and Adverum are key players in the R&D for solutions targeting wet age-related macular degeneration (AMD), a market driven by aging populations and advanced AI diagnostics.Some support1 report
-
Evkeeza, a drug developed by Regeneron Pharmaceuticals, received expanded regulatory approvals in Canada and the European Commission.Some support1 report
-
Regeneron Pharmaceuticals' stock loss was below the S&P 500 gain on July 17, 2025.Some support2 reports
-
Regeneron Pharmaceuticals sponsored the Regeneron STEM Teaching Fellowship, announcing the selection of Anna Dowd and Kate Sheil for the program.Some support1 report
-
FDA inspection observations caused anticipated delays regarding Eylea HD, impacting Regeneron Pharmaceuticals and related development partners like Roche and Vabysmo.Some support2 reports
-
Regeneron Pharmaceuticals' stock price was influenced by its actual earnings results compared to estimates on July 25, 2025.Some support1 report
-
Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.Some support2 reports3 developments inside
-
Collaboration agreement for Evkeeza and distribution rights obtained by ORBIT and Regeneron in Turkey and the European Economic Area.Some support1 report
-
Intellia Therapeutics and Regeneron Pharmaceuticals entered into a co-development and co-promotion agreement for the drug nex-z, with revenues tied to cost reimbursements.Some support2 reports
-
Regeneron Pharmaceuticals awarded a prize to Sreekar Mantena, an MIT candidate and Broad Institute nominee, who works under Soumya Raychaudhuri.Some support2 reports
-
Regeneron Pharmaceuticals and its team highlighted the strong commercial performance of key products and anticipated decisions regarding EYLEA HD and Libtayo use.Some support1 report
-
FDA regulatory action delays are prolonging uncertainty for Regeneron Pharmaceuticals.Some support2 reports
-
The FDA pushed back review timelines for Eylea HD, classifying the submission as a major amendment, while Novo Nordisk acquired the manufacturer.Well supported4 reports
-
Immuneering, Regeneron Pharmaceuticals, and Eli Lilly signed agreements regarding clinical trials and supply for specific drugs.Some support1 report
-
FDA review is pending for cemdisiran submission from Regeneron Pharmaceuticals.Some support1 report
-
The FDA approved Linvoseltamab for the treatment of multiple myeloma, a drug developed by Regeneron Pharmaceuticals.Some support1 report
-
The FDA declined approval for odronextamab, a drug that was already approved in Europe.Some support1 report
-
Exact Sciences and Regeneron Pharmaceuticals operate within the immuno-oncology industry.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Regeneron Pharmaceuticals
Events traced to Regeneron Pharmaceuticals, step by step, newest firstAround Regeneron Pharmaceuticals this week
News at the entities that move Regeneron Pharmaceuticals most-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Regeneron Pharmaceuticals
-
Morgan Stanley OperationalCitigroup and Morgan Stanley raised price targets for Western Midstream Partners on July 14, 2026.Moves Regeneron Pharmaceuticals
-
European Commission StructuralThe European Commission has launched an investigation into fraud and consumer protection practices involving booking.com.Moves Regeneron Pharmaceuticals
-
Intellia Therapeutics OperationalIntellia Therapeutics and BeyondSpring are identified as small-cap healthcare companies.Moves Regeneron Pharmaceuticals
-
Leerink partners OperationalLeerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.Moves Regeneron Pharmaceuticals
-
Truist Financial OperationalTruist Financial, U.S. Bancorp, and Citigroup are reported as top holdings in various regional and financial sector ETFs.Moves Regeneron Pharmaceuticals
Connections
The 40 strongest of 266, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Regeneron Pharmaceuticals' drug development and market approval processes.
-
Sanofi Operational
The two companies are engaged in a joint venture, co-developing and co-marketing the Dupixent eczema treatment, which includes shared revenues and royalty streams.
-
Intellia Therapeutics Operational
Intellia and Regeneron are engaged in a formal collaboration to co-develop and co-promote the genome-editing candidate nex-z.
-
Michael Burry Transactional
Burry is actively betting on the recovery and future potential of Regeneron despite market doubts.
-
Novo Nordisk Operational
Novo Nordisk supplies filling services for Regeneron vials while both companies actively compete in the chronic disease management market.
-
23andMe Structural
Regeneron acquired 23andMe's genetic data and assets, integrating them into its R&D pipeline.
-
Immuneering (United States) Transactional
Immuneering provides clinical trial and supply agreements for its compounds to Regeneron Pharmaceuticals.
-
SEC Structural
Regeneron Pharmaceuticals is required to file reports regarding institutional holdings with the SEC.
Show all 40 connections
-
Veeva Systems Structural
Veeva Systems provides global CRM software solutions for Regeneron Pharmaceuticals' commercial teams.
-
Biogen Operational
Regeneron and Biogen are active competitors across ophthalmology, immunology, and oncology therapeutic areas.
-
Morgan Stanley Operational
Morgan Stanley actively analyzes and influences the market valuation of Regeneron Pharmaceuticals through reports and conference presence.
-
Andrew J. Murphy Structural
Andrew J. Murphy serves as Co-Chief Scientific Officer at Regeneron Pharmaceuticals.
-
Natera Operational
Both Natera and Regeneron Pharmaceuticals are identified as major competitors in the immuno-oncology market.
-
Leerink partners Operational
Leerink Partners provides financial analysis and rating updates for Regeneron Pharmaceuticals.
-
European Commission Structural
The European Commission holds final regulatory authority over recommendations affecting Regeneron Pharmaceuticals.
-
Sanofi Operational
Sanofi and Regeneron are partners in the joint development of the Praluent cholesterol medication.
-
Truist Financial Operational
Truist Financial has influenced the market perception and valuation of Regeneron Pharmaceuticals through changes in its stock price objective.
-
representative Transactional
The representative completed a sale of shares in Regeneron Pharmaceuticals.
-
National Pension Service Structural
The National Pension Service increased its stake in Regeneron Pharmaceuticals stock holdings.
-
LinkedIn Operational
Regeneron Pharmaceuticals utilizes LinkedIn as a platform for company communication and presence.
-
Dodge & Cox Transactional
Dodge & Cox increased its investment stake in Regeneron Pharmaceuticals.
-
UBS Mentioned together
UBS provides financial analysis and price targets for Regeneron Pharmaceuticals.
-
Precision BioSciences Operational
The two companies are actively competing against each other within the biotechnology sector.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides financial analysis, including price targets and ratings, for Regeneron Pharmaceuticals.
-
Sanofi (Japan) Mentioned together
Both companies are noted for operating in the pharmaceutical sector and reporting results from late-stage studies.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports consensus market ratings and financial data for Regeneron Pharmaceuticals.
-
Society for Science Mentioned together
The two entities jointly announced the results of a prestigious science competition.
-
Bayer Operational
Bayer and Regeneron are engaged in a joint development partnership for the drug Eylea HD, with Regeneron holding US exclusive rights.
-
TD Cowen Mentioned together
TD Cowen, as an analyst firm, has published coverage including a raised price objective and rating for Regeneron Pharmaceuticals.
-
HSBC Mentioned together
HSBC provides financial analysis and price targets for Regeneron Pharmaceuticals stock.
-
JPMorgan Chase Mentioned together
JPMorgan Chase provides financial analysis and rating coverage on Regeneron Pharmaceuticals.
-
Wave Life Sciences Mentioned together
The two healthcare companies are mentioned in the same context as peers being compared.
-
Abbott Laboratories Mentioned together
Both companies operate within the highly competitive biotechnology and pharmaceutical industry sector.
-
Northwest Biotherapeutics Operational
Market analysis compares Northwest Biotherapeutics and Regeneron Pharmaceuticals regarding their financial performance and outlook.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial market analysis and price targets for Regeneron Pharmaceuticals.
-
Wells Fargo Mentioned together
Wells Fargo provides investment ratings and price targets for Regeneron Pharmaceuticals stock.
-
Study Transactional
Regeneron utilized the services or products of Study for a clinical trial.
-
National Building Museum Shared context
The company utilized the museum as the location for an announcement ceremony.
-
Saratoga Springs Structural
Regeneron Pharmaceuticals is developing a new facility within Saratoga Springs.
-
Nasdaq Shared context
Regeneron Pharmaceuticals is listed and traded on the Nasdaq exchange.
History
Events by the month they beganOctober 2026
3 eventsSeptember 2026
6 events- Regeneron Pharmaceuticals and Wave Life Sciences are being compared as healthcare companies.
- Sanofi completed the repayment of a development balance.
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
- Regeneron Pharmaceuticals filed required reports with the SEC regarding institutional holdings on September 8, 2026.
- Michael Burry bets on Regeneron recovery despite market skepticism, holds large call positions in UnitedHealth Group, and views Lululemon as undervalued.
- MarketBeat provided stock performance data and analyst recommendations for Regeneron Pharmaceuticals and IDEAYA Biosciences.
August 2026
7 events- The National Pension Service increased its stock holdings in Regeneron Pharmaceuticals.
- FDA approved Pasatru for FOP treatment.
- Regeneron Pharmaceuticals has committed to adopting Veeva Vault CRM globally for its commercial teams, utilizing Veeva's specialized platform services.
- Society for Science and Regeneron Pharmaceuticals jointly announced the results of a prestigious science competition at the National Building Museum.
- Dodge & Cox grew its stake in Regeneron Pharmaceuticals stock.
- Regeneron Pharmaceuticals and Biohaven Ltd. announced a clinical supply agreement for combination therapy on August 14, 2026.
- Market analysis compares the financial performance and outlook of Northwest Biotherapeutics and Regeneron Pharmaceuticals.
Show 2 earlier months
July 2026
5 events- Sanofi and Regeneron Pharmaceuticals announce a joint initiative to develop Praluent cholesterol medication and initiatives like TrumpRx.gov.
- Regeneron and Sanofi are seeking FDA approval for EYLEA HD pre-filled syringe and discussing collaboration expansion.
- Regeneron Pharmaceuticals is developing a new facility in the city of Saratoga Springs.
- Regeneron conducted the clinical trial for a study related to co-developing new therapies.
- Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.
June 2026
39 events- Anne Wojcicki uses her nonprofit to acquire 23andMe amidst a lawsuit led by Letitia James regarding genetic data privacy, while TTAM submitted a higher unsolicited offer than Regeneron.
- Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.
- Tariffs benefit undervalued AI stocks, and a partnership expands global production footprint for a company.
- Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.
- Omeros partnered with Novo Nordisk on zaltenibart development, while Intellia and Regeneron formed a collaboration on co-developing therapies. Separately, the FDA approved Omeros' Yartemlea for TA-TMA treatment.
- Analyst coverage was mentioned in an article regarding Regeneron Pharmaceuticals and Royal Bank of Canada on June 16, 2026.
- Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.
- Regeneron Pharmaceuticals operates in Westchester and Hudson Valley, contributing to the local economy and being integrated into the NewYork-Presbyterian system.
- Regeneron Pharmaceuticals purchased shares in a concurrent private placement, with Leerink Partners serving as part of the underwriting syndicate.
- Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.
- Regeneron Pharmaceuticals received accelerated FDA approval for a drug and partnered with Onco360.
- Regeneron recorded net product sales of Eylea in the US, and Bayer confirmed its collaboration on the drug's development.
- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Roche and Regeneron Pharmaceuticals are capitalizing on the growing demand for vision care driven by aging populations.
- Regeneron Pharmaceuticals matched donations to support the Good Days fund.
- Incyte and Regeneron Pharmaceuticals are identified as major players in the immuno-oncology industry.
- FDA granted accelerated approval for Regeneron's drug, which is expected for MM cases in the US in 2025.
- FDA granted accelerated approval for Lynozyfic, and J.P. Morgan reiterated a Buy rating for the company.
- The healthcare sector experienced a discount against the broader market on August 22, 2025, influenced by political uncertainties and government policies targeting prescription drug prices.
- RBC raised the price target on Regeneron Pharmaceuticals on July 7, 2025.
- MAIA Biotechnology began clinical trials, dosing the first patient in Taiwan and screening in Europe and Asia, with Regeneron providing Libtayo.
- Regeneron and Adverum are key players in the R&D for solutions targeting wet age-related macular degeneration (AMD), a market driven by aging populations and advanced AI diagnostics.
- Evkeeza, a drug developed by Regeneron Pharmaceuticals, received expanded regulatory approvals in Canada and the European Commission.
- Regeneron Pharmaceuticals' stock loss was below the S&P 500 gain on July 17, 2025.
- Regeneron Pharmaceuticals sponsored the Regeneron STEM Teaching Fellowship, announcing the selection of Anna Dowd and Kate Sheil for the program.
- FDA inspection observations caused anticipated delays regarding Eylea HD, impacting Regeneron Pharmaceuticals and related development partners like Roche and Vabysmo.
- Regeneron Pharmaceuticals' stock price was influenced by its actual earnings results compared to estimates on July 25, 2025.
- Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.
- Collaboration agreement for Evkeeza and distribution rights obtained by ORBIT and Regeneron in Turkey and the European Economic Area.
- Intellia Therapeutics and Regeneron Pharmaceuticals entered into a co-development and co-promotion agreement for the drug nex-z, with revenues tied to cost reimbursements.
- Regeneron Pharmaceuticals awarded a prize to Sreekar Mantena, an MIT candidate and Broad Institute nominee, who works under Soumya Raychaudhuri.
- Regeneron Pharmaceuticals and its team highlighted the strong commercial performance of key products and anticipated decisions regarding EYLEA HD and Libtayo use.
- FDA regulatory action delays are prolonging uncertainty for Regeneron Pharmaceuticals.
- The FDA pushed back review timelines for Eylea HD, classifying the submission as a major amendment, while Novo Nordisk acquired the manufacturer.
- Immuneering, Regeneron Pharmaceuticals, and Eli Lilly signed agreements regarding clinical trials and supply for specific drugs.
- FDA review is pending for cemdisiran submission from Regeneron Pharmaceuticals.
- The FDA approved Linvoseltamab for the treatment of multiple myeloma, a drug developed by Regeneron Pharmaceuticals.
- The FDA declined approval for odronextamab, a drug that was already approved in Europe.
- Exact Sciences and Regeneron Pharmaceuticals operate within the immuno-oncology industry.